Propellon Therapeutics Inc.

Ontario Institute for Cancer Research (oicr)

Ontario Institute for Cancer Research (oicr) and Sinai Health System

Ontario Institute for Cancer Research

Gennady Poda

Methvin Benjamin Isaac

Ahmed Mamai

Rima Al-Awar

David Uehling

Brian Wilson

Pandiaraju Subramanian

Babu Joseph

Yong Liu

Michael Prakesch

Carlos Armando Zepeda-Velazquez

Anh My Chau

Iain Watson

Frank Sicheri

Julia Kathleen Stille

Justin-Alexander Morin

Julia Katheleen Stille

Ganna Posternak

The present application is directed to compounds of Formula I:

Substituted carboxamides as inhibitors of WDR5 protein-protein binding

The present application relates to novel compounds of Formula (I) containing a E3 ubiquitin ligase binding moiety linked to a Raf protein kinase binding moiety. The present application also includes methods and uses of the compounds, for example, for inhibiting and/or degrading V600E mutant B-Raf. I

Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses

The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners. 

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer. 

Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof

The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Growing community of inventors

Toronto, Canada

Gennady Poda